ArticleInternational journal of cosmetic science2025
Clinical efficacy of OS-01 peptide formulation in reducing the signs of periorbital skin aging.
Article in International journal of cosmetic science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Dermocosmetics for Periocular Aging: Evidence, Mechanisms, and Integration with Aesthetic Procedures. A Narrative Review.Dermatology and therapy · 2026Review
- A Mechanism-Based Framework for Anti-Aging Strategies: From Metabolic Regulation to Senotherapy and Stem Cell-Based Interventions.Aging cell · 2026Review
- Regenerative Approaches to Enhance the Skin Microenvironment and Boost Aesthetic Efficacy: A Narrative Review.International journal of molecular sciences · 2026Review
- Clinical efficacy of OS-01 peptide formulation in reducing the signs of periorbital skin aging.International journal of cosmetic science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aging of the skin, particularly around the periorbital region, is a complex process characterized by the accumulation of senescent cells, decreased collagen production, and reduced skin elasticity, leading to visible signs such as fine lines, wrinkles, and sagging.
objectiveThis study investigates the efficacy of a novel topical formulation, OS-01 EYE, containing the senomorphic peptide, OS-01, along with other active ingredients, in improving the skin around the eyes.
methodsA 12-week clinical study was conducted with 22 participants who applied OS-01 EYE twice daily. Assessments included bioinstrumental measurements of skin hydration, barrier function, firmness, and elasticity, as well as expert photographs grading fine lines, wrinkles, under-eye puffiness, and dark circles.
resultsAfter 12 weeks of product use, transepidermal water loss (TEWL) decreased by 17.33%, hydration increased by 32.49%, skin firmness improved by 10.19%, and elasticity increased by 25.58%, compared to baseline, which was all statistically significant. Expert grading revealed a decrease in fine lines and wrinkles, under-eye puffiness, and dark circles over the study period. Furthermore, subjective assessments showed that 95.46% of participants reported improvements in overall appearance.
conclusionThe OS-01 EYE formulation was found to be safe and effective in mitigating the visible signs of aging in the periorbital region, making it a potent treatment option for enhancing periorbital skin health, function, and appearance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.